ERISA Ledger · U.S. DOL EBSA Form 5500 (2024)

Revance Therapeutics, INC.

Official 2024 U.S. DOL Form 5500 summary for Revance Therapeutics, INC. (Revance Therapeutics, INC. 401(k) P/s Plan · EIN 77-0551645 · PN 001): $69.09M net assets, 538 active participants, and $18.11 per $10,000 (18.11 bps).

Reported Form 5500 Fee & Service Summary

Plan SponsorRevance Therapeutics, INC.
Filing IdentifierRevance Therapeutics, INC. 401(k) P/s Plan · EIN 77-0551645 · PN 001
Plan Category & State401(k) Defined Contribution (TN)
Asset-Size Peer Cohort$25M-$100M
Plan Net Assets (2024)$69.09M
Active Participants538
Direct Admin Fee Rate$18.11 per $10,000 (18.11 bps)
Cohort Peer Median$19.23 per $10,000 (19.23 bps)
Primary Recordkeeper / ProviderFidelity Investments
Schedule H Line 4a RemittanceTimely Employer Remittance (0 reported on Line 4a)

Browse all 78,373 plans & Schedule C vendors · Methodology · Meru AI